ClinicalTrials.gg
RecruitingNCT03895359TACEUpdated Mar 11, 2025

Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma

A Phase 3 interventional study of Stereotactic Body Radiation and Transarterial Chemoembolization in Hepatocellular Carcinoma, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2019; still recruiting 7 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Carcinoma, Hepatocellular with a site in Canada — 23 open to participants now, 39 under way, 12 of them phase 3. Carcinoma, Hepatocellular · Canada.

Planned enrollment
56th of 114
128 · median 127
Started
2019
with 7 others
Phase 3
41 of 128
5 open now
Primary completion
2027-06
later than 20 of 38 live
Registered
87th of 128
by date

Among the 128 studies in Carcinoma, Hepatocellular with a site in Canada, this one is the 56th largest by planned enrollment of the 114 interventional ones that give a count, is one of 8 that started in 2019, is one of 41 in phase 3, reaches primary completion later than 20 of the 38 other live ones, and was the 87th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

23 of the 128 studies in Carcinoma, Hepatocellular with a site in Canada are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Carcinoma, Hepatocellular with a site in Canada, or all of them as a file.
02

Study summary

Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of the liver and liver cancer. Unfortunately, the tumour grows after TACE in many patients.

A new treatment using a specialized radiation procedure called Stereotactic ablative body radiotherapy (SBRT) may increase the chance to control liver cancer. SBRT allows radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. The purpose of this study is to find out if TACE alone versus TACE plus SBRT is better for you and your liver cancer.

Read the detailed description

HCC tends to remain within the liver and, therefore, cure with preserved liver function is possible.4 Treatments with relatively high success rates include surgical resection and liver transplantation. Surgical resection results in 5-year survival rates of approximately 60%-70%.4 Liver transplantation can cure both the cancer and underlying liver disease with 4-year survival for HCC within the Milan criteria (single HCC \<5 cm or ≤3 HCC \<3 cm) at 70%-85% after transplantation.5 Unfortunately, most patients are not resectable due to the extent of disease. Transarterial chemoembolization (TACE) has become the mainstay of treatment for unresectable HCC. 5,6 TACE is relatively safe due to the liver's unique vascular supply from the portal vein. HCC on the other hand, is supplied almost entirely by branches of the hepatic artery.7 In a randomized controlled trial for unresectable HCC not suitable for a curative intent, transarterial chemoembolisation or TACE were compared to conservative treatment.8 TACE induced objective responses (complete and partial response) that were sustained for at least 6 months in 35% of cases. Survival probabilities at 1 year and 2 years were 82% and 63% for TACE, significantly better than 63% and 27% obtained with conservative treatment. Overall survival at 1 and 2 years was also significantly better for the chemoembolization group 57% and 31% vs. 32% and 11%. However, many patients have large tumours and response rates to TACE decline rapidly with increasing size.9 TACE alone resulted in 2 year overall survivals of 42%, 0 and 0 for lesions 5-7cm, 8-10cm, and >10cm, respectively. Therefore, additional locally ablative treatments are being sought. In the same report, TACE plus radiation resulted in 2 year overall survivals of 63%, 50% and 17% for lesions 5-7cm, 8-10cm, and >10cm, respectively.9 External beam radiotherapy has long been considered to have a very limited role in the treatment of liver tumors. This has historically been because minimum dose required for local ablation exceeded the dose that would result in liver toxicity.10,11 The technical development of stereotactic body radiation therapy (SBRT), alone or in combination with TACE, renewed interest in radiation for HCC.12,13 For SBRT, advanced techniques are used to very accurately deliver a high total dose to the target in a small number of daily fractions while avoiding dose delivery to surrounding healthy structures. This research in HCC was done mainly by two groups, in Michigan and Stockholm, who demonstrated that the delivery of high doses of radiation to limited volumes of the liver had promising results in terms of local control and survival with acceptable toxicity.14,15 SBRT is offered as an ablative radical local treatment. In total as of 2015, eleven primary series reported on tumor response and survival of around 300 patients who have been treated with stereotactic body radiation therapy as primary therapy for HCC (Table A). The reported percentage of objective responses defined as complete and partial was ≥64% in 7 of 8 series. Median survival between 11.7 and 32 months has been observed. Toxicity, based on multiple case series trials, indicate that the treatment is considered safe. The most common CTC grade 3-4 toxicity was elevation of liver enzymes. 16-19 For unresectable cases, both TACE and SBRT have been used safely and with good efficacy as separate treatments. Particularly for larger lesions that are more commonly seen in London, the outcome remains suboptimal compared to surgery. Combined treatment case series have shown dramatic results (Table B), but there has not been any randomized trial to compare the value of combining the two modalities. Therefore, a clinical study comparing SBRT and SBRT+TACE will be significant as it addresses a common problem in one of the two most deadly cancers.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary hepatobiliary cancer confirmed pathologically
  • Non - lymphoma liver confirmed pathologically
  • Radiographic liver lesions most consistent with metastases, in a patient with known proven non - lymphoma cancer and a previously negative CT or MRI of the liver
  • Hepatocellular carcinoma diagnosed with vascular enhancement of the lesion consistent with hepatocellular carcinoma, and with an elevated AFP, in the setting of cirrhosis or chronic hepatitis.
  • ≤ 5 liver lesions measurable on a contrast - enhanced liver CT or MRI performed within 90 days prior to study entry.
  • Primary liver lesion or liver metastases measuring ≤ 25 cm.
  • Extrahepatic cancer is permitted if liver involvement is judged to be life - limiting.
  • All intrahepatic disease must be encompassed within the radiation fields according to protocol criteria.
  • Patient must be judged medically or surgically unresectable
  • Zubrod Performance Scale = 0 - 3
  • Age > 18
  • All intrahepatic disease must be amenable to TACE
  • Previous liver resection or ablative therapy is permitted.
  • Chemotherapy must be completed at least 2 weeks prior to radiation therapy or TACE, and not planned to be administered for at least 1 week (for anthracyclines at least 4 weeks) after completion of treatment.
  • > 6 months.
  • Women of and male participants must practice adequate .
  • Patient must sign study specific prior to study entry.

Pretreatment Evaluations Required for Eligibility:

  • A complete history and general physical examination.
  • CBC, , Total , albumin, alkaline phosphatase, , AST within 4 weeks prior to study entry. Appropriate levels are as follows:
  • (ANC) ≥ 1,500 cells / mm3
  • ≥ 70,000 cells / mm3
  • ≥ 8.0 g / dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g / dl is acceptable.)
  • Total bilirubin \< 3 mg / dL
  • Prothrombin time / INR \< 2 (if not on anticoagulants)
  • Albumin ≥ 28 g / L
  • AST and ALT \< 10 times

Exclusion criteria

Exclusion Criteria:

  • Severe cirrhosis or liver failure defined as > B7
  • Primary liver tumor or liver > 25 cm in maximal dimension.
  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
  • Severe, active co-morbidity, defined as limiting the patients life to less than 6 months
  • Active hepatitis or liver failure.
  • Pregnancy, nursing women, or women of , and men who are sexually active and not willing/able to use medically acceptable forms of ; this exclusion is necessary because the treatment involved in this study may be teratogenic.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
128 participants (estimated)

Study arms

  • Active comparator
    Transarterial Chemoembolization (TACE)

    Transarterial Chemoembolization (TACE)

    Drug: Transarterial Chemoembolization

  • Active comparator
    TACE Plus Stereotactic Body Radiation Therapy (SBRT)

    Stereotactic Body Radiation Therapy (SBRT)

    Radiation: Stereotactic Body Radiation

Interventions

  • RadiationStereotactic Body Radiation

    For patients randomized to the SMRT arm, SBRT is to be delivered over 5 fractions delivered over 5 to 15 days.

  • DrugTransarterial Chemoembolization

    Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.

    Also known as: TACE

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall Survival-number of patients alive censored for deaths by any cause

    Time frame: At 2 years from start of treatment

  2. Time to Intrahepatic Progression

    This will be measured using the modified RECIST (Response evaluation criteria in solid tumors) criteria

    Time frame: Pre-treatment, at 1 month and 3 month follow-up, and at follow-up every 3 months up to 2 years

Secondary outcomes

  1. Measurement of Response Rate

    Modified RECIST (Response Evaluation Criteria in Solid Tumors) criteria

    Time frame: The sum of the longest diameter (LD) for all target lesions will be calculated and reported as the baseline sum LD. The baseline sum LD will be used as reference by which to characterize the objective tumor.

  2. Local Failure

    Within 1 cm from the original tumor volume

    Time frame: 5 years

  3. Extrahepatic failure

    This will be defined as any lesion found to be new or progressing outside the hepatic organ.

    Time frame: Pre-treatment, at 1 month and 3 month follow-up, and at follow-up every 3 months up to 2 years

  4. Time to intrahepatic progression

    This will be measured using the modified RECIST (Response evaluation criteria in solid tumors) criteria

    Time frame: Pre-treatment, at 1 month and 3 month follow-up, and at follow-up every 3 months up to 2 years

  5. Radiation Therapy Overall Toxicity Assessment

    CTC V4.0 (Common Terminology Criteria version 4.0)

    Time frame: Weekly during treatment, 1 and 3 month follow-up, and every 3 months thereafter up to 2 years

  6. Radiation Therapy Classic Radiation Toxicity Assessment

    Classic RILD (Radiation-induced liver disease)

    Time frame: Weekly during treatment , 1 and 3 month follow-up, and every 3 months thereafter up to 2 years

  7. Radiation Therapy Non-Classic Toxicity Assessment

    Non-classic RILD (Radiation-induced liver disease)

    Time frame: Weekly during treatment, 1 and 3 month follow-up, and every 3 months thereafter up to 2 years

  8. Radiation Therapy Toxicity Assessment

    Measured using Child-Pugh score to indicate the severity of toxicity. Five variables are considered: presence of ascites, encephalopathy, serum levels of albumin, total bilirubin and prolongation of the clotting time. Each of these variables is assigned a score between 1 and 3 according to its severity or degree of abnormality. The sum of the five scores is used to assign a "Child-Pugh grade" of A, B or C to the patient's clinical condition at that point in time. Grade A indicates a well-functioning liver, Grade B indicates significant functional compromise, Grade C indicates decompensation of the liver.

    Time frame: Patients will be assessed at least once during radiation therapy for toxicity

  9. Change in Health related Quality of Life (QOL)

    Measured using the EORTC (European Organisation for Research and Treatment of Cancer) QLQ H\&N35 (Quality of Life Questionnaire Head \& Neck). According to the EORTC scoring guidelines All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: Pre-Treatment, weekly during treatment, 1 and 3 month follow-up, and every 3 months thereafter

  10. Overall Quality of Life (QOL)

    QLQC30 (Quality of Life Questionnaire version 3)

    Time frame: Pre-Treatment, weekly during treatment, 1 and 3 month follow-up, and every 3 months thereafter up to 2 years

  11. Liver Related Quality of Life (QOL)

    FACT-L (Functional Assessment of Cancer Therapy-Lung)

    Time frame: Pre-Treatment, weekly during treatment, 1 and 3 month follow-up, and every 3 months thereafter up to 2 years

  12. Cost-benefit

    A cost benefit analysis will be used to evaluate the total anticipated cost of the project and compare it to the total expected benefits.

    Time frame: Through study completion, an average of 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Jun 2027, 96 months after the start.

Of 86 non-industry phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 109. This study's planned 96 months is above that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2019
First posted
Mar 29, 2019
StartActual
May 27, 2019
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03895359
Collaborators
CancerCare Manitoba
Responsible party
Michael Lock (Principal Investigator, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's) — Principal investigator
First posted
Mar 29, 2019
Start date
May 27, 2019
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Mar 11, 2025

Study contacts

Michael Lock, M.D.
Contact
michael.lock@lhsc.on.ca
519-685-8650
Michael Lock, M.D.
principal investigator · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion